**Disease Burden**

In 2022, an estimated 10.6 million people fell ill with tuberculosis (TB) worldwide, of which 450,000 incident cases of rifampicin-resistant or multidrug-resistant TB. About 1.5 million people die from TB each year. Most of the people who fall ill with TB live in LMICs.

**Clinical Relevance**

BTZ-043 is an investigational DprE1 inhibitor. Safety and efficacy data are still not mature.

**Service Delivery Enablers**

BTZ-043, an oral TB treatment, may be paired with existing TB drugs, some not widely accessible.

**Manufacturing**

There are still no adequate data to assess manufacturing complexity.

**Market**

BTZ-043 is still in the R&D pipeline and therefore little is known about its potential positioning, pricing, and overall access plans.

**Intellectual Property Landscape**

BTZ-043 primary patent has been granted in many LMICs and is expected to expire in May 2026. Secondary patents have not been identified.

**Regulatory**

BTZ-043 does not have regulatory approval yet and there is insufficient data to determine bioequivalence studies requirements or the likelihood of a biowaiver.